Press Releases

Date Title
Toggle Summary vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update
SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively enrolling HIGH POINT, N.C. , Oct. 30, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.
View HTML
Toggle Summary vTv to Host Key Opinion Leader Event to Discuss the Type 1 Diabetes Treatment Landscape and Emerging Therapies as Adjuncts to Insulin
HIGH POINT, N.C. , Oct. 03, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today announced that the Company will host a key opinion leader (KOL) presentation and webcast discussing the type 1 diabetes (T1D) treatment landscape and emerging therapies in New York City on Tuesday,
View HTML
Toggle Summary vTv Therapeutics Presents Additional Positive Data from the Phase 2 Simplici-T1 Study in Patients with Type 1 Diabetes at 55th Annual Meeting of the European Association for the Study of Diabetes
Patients treated with TTP399 had improved Time in Range (TIR), reduced time in hyperglycemia, fewer hypoglycemic events, and lower bolus insulin dose HIGH POINT, N.C. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), today presented additional positive data from its phase
View HTML
Toggle Summary vTv Therapeutics to Present Posters at Two Scientific Conferences in September
 Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program Pre-Clinical Data in NASH with the NRF2/Bach1 Program  HIGH POINT, N.C. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company with
View HTML
Toggle Summary vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
HIGH POINT, N.C. , Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it is scheduled to present a general company
View HTML
Toggle Summary vTv Therapeutics to Participate in Upcoming Canaccord Genuity and Solebury Trout Conferences
HIGH POINT, N.C. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for diabetes and Alzheimer’s disease, today announced that it will be participating in the
View HTML
Toggle Summary vTv Therapeutics Announces 2019 Second Quarter Financial Results and Update
HIGH POINT, N.C. , July 31, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter that ended June 30, 2019 , and provided an update on recent achievements and upcoming events. “We made significant progress during the second quarter,”
View HTML
Toggle Summary vTv Therapeutics to Present at 2019 Alzheimer’s Association International Conference
HIGH POINT, N.C. --(BUSINESS WIRE)--Jul. 15, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will make an oral
View HTML
Toggle Summary vTv Therapeutics Initiates Phase 2 Clinical Trial Evaluating Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes
HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 27, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the first patient has been screened for the phase 2 proof of concept study evaluating the safety and efficacy of azeliragon in patients with mild Alzheimer's disease and type 2 diabetes.
View HTML
Toggle Summary vTv Therapeutics Announces Positive Topline Results from Part 1 of the Phase 2 Simplici-T1 Trial in Patients with Type 1 Diabetes
TTP399, a novel glucokinase activator shows statistically significant reduction in HbA1c without increases in ketones or hypoglycemia HIGH POINT, N.C. --(BUSINESS WIRE)--Jun. 6, 2019-- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced positive results from the primary analysis of Part 1 of the
View HTML